Gilead Sciences, Inc. (GILD)
167.47
-2.86
(-1.68%)
USD |
NASDAQ |
Nov 03, 16:00
168.00
+0.53
(+0.32%)
After-Hours: 05:35
Gilead Sciences Free Cash Flow : 13.78B for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | 13.78B |
| June 30, 2026 | 12.94B |
| March 31, 2026 | 10.23B |
| December 31, 2025 | 9.456B |
| September 30, 2025 | 9.162B |
| June 30, 2025 | 9.369B |
| March 31, 2025 | 9.844B |
| December 31, 2024 | 10.30B |
| September 30, 2024 | 9.431B |
| June 30, 2024 | 6.896B |
| March 31, 2024 | 7.899B |
| December 31, 2023 | 7.421B |
| September 30, 2023 | 7.853B |
| June 30, 2023 | 8.926B |
| March 31, 2023 | 8.387B |
| December 31, 2022 | 8.344B |
| September 30, 2022 | 9.007B |
| June 30, 2022 | 9.415B |
| March 31, 2022 | 9.953B |
| December 31, 2021 | 10.80B |
| September 30, 2021 | 9.491B |
| June 30, 2021 | 8.472B |
| March 31, 2021 | 8.698B |
| December 31, 2020 | 7.518B |
| September 30, 2020 | 8.16B |
| Date | Value |
|---|---|
| June 30, 2020 | 8.764B |
| March 31, 2020 | 8.377B |
| December 31, 2019 | 8.319B |
| September 30, 2019 | 8.039B |
| June 30, 2019 | 7.385B |
| March 31, 2019 | 6.625B |
| December 31, 2018 | 7.476B |
| September 30, 2018 | 7.912B |
| June 30, 2018 | 8.432B |
| March 31, 2018 | 10.56B |
| December 31, 2017 | 11.31B |
| September 30, 2017 | 12.47B |
| June 30, 2017 | 14.04B |
| March 31, 2017 | 15.15B |
| December 31, 2016 | 16.30B |
| September 30, 2016 | 17.31B |
| June 30, 2016 | 16.99B |
| March 31, 2016 | 17.96B |
| December 31, 2015 | 19.58B |
| September 30, 2015 | 17.73B |
| June 30, 2015 | 17.83B |
| March 31, 2015 | 16.43B |
| December 31, 2014 | 12.26B |
| September 30, 2014 | 10.07B |
| June 30, 2014 | 6.872B |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.796B |
| AbbVie, Inc. | 18.21B |
| Biogen, Inc. | 1.644B |
| Amgen, Inc. | 10.18B |
| Regeneron Pharmaceuticals, Inc. | 3.628B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 5.035B |
| Cash from Investing (Quarterly) | -244.00M |
| Cash from Financing (Quarterly) | -1.528B |
| Free Cash Flow Per Share (Quarterly) | 3.835 |
| Free Cash Flow to Equity (Quarterly) | 4.813B |
| Free Cash Flow to Firm (Quarterly) | 5.011B |
| Free Cash Flow Yield | 6.58% |